Gillard has not disclosed the sale price of Ridseywe, but the Institute for Clinical and Economic Assessment (“ICER”), a drug price analyst, has calculated that the price of using Redsie to treat each patient with new coronary pneumonia could be as high as $4,500. On Friday, the U.S. Food and Drug Administration granted Redcieway “emergency use” permits because clinical trials showed it could shorten the course of new coronary pneumonia by 31 percent, meaning patients can spend four days in hospital.
ICER often believes that drug prices are too high compared to their own value. As a result, ICER often interacts with pharmaceutical companies.
But ICER said Friday that it is reasonable to price up to $4,500 per treatment (10 days) at Redsey. However, ICER also noted that its calculations are based on preliminary data and could change in the future.
But Mr Gilead said it was too early to develop a long-term pricing strategy. Gilead has announced that it will donate the current 140,000 sessions of Ridsey. For many investors and Wall Street analysts, the Redwest price is the number one puzzle.
Michael Yee, a biotech analyst at Jefferies, said in an investment report Released On Sunday that “icER’s estimate of the value of the drug is usually conservative, and it’s interesting that it’s reasonable to think that Redsey is priced up to $4,500 per course.” “
Michael Eyre says that at $1,000 per course, if red-syweed could sell $1 million for the course, the business alone could be paid $1 billion this year.
Gilead CEO Daniel O’Day said Sunday that new coronary pneumonia patients will be able to use Ridsywe in the next few days.
In addition, an article published in Journal of Virus Iro estimated the cost of production at Redseyway for a course of treatment at $9.32. If a course of Redsie costs $4,500, the drug’s profit margin will be staggeringly high.